Research and analysis

Impact assessment opinion: Falsified Medicines Directive 2011/62/EU

Evaluation of the Department of Health impact assessment for Falsified Medicines Directive 2011/62/EU

• From: Regulatory Policy Committee
• Published: 27 August 2014

Documents

Impact assessment opinion: Falsified Medicines Directive 2011/62/EU

PDF, 70.5 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email enquiries@bis.gsi.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

View the impact assessment under evaluation

The Regulatory Policy Committee (RPC) gives independent advice to government on the quality of analysis supporting new regulations.

Following scrutiny of an impact assessment (IA) carried out prior to a regulatory proposal, the RPC provides an ‘opinion’ on the quality of analysis and evidence presented in the IA. This opinion then informs the decisions of ministers as to whether they proceed or not with the proposal.

Published 27 August 2014